Member Directory
Primary tabs
Below all members are listed in alphabetical order. Click the tabs above to view working group members.
Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University and Senior Director for Research at ICAP. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Dr. Ammerman is a Researcher at Erasmus University Medical Center Rotterdam, Department of Medical Microbiology & Infectious Diseases; and an adjunct research associate at the Johns Hopkins Center for Tuberculosis Research. Conflict of Interest: Receives research funding from Janssen Pharmaceutica. |
Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. Conflict of Interest: Receives royalties from emocha Health, miDiagnostics, consulting fees from Merck, Hologic, and grant funding from emocha Health. |
Peggy is a Group Medical Director and Global Development lead for HCV products at AbbVie Inc. Conflict of Interest: Receives salary support from AbbVie. |
Richard E. Chaisson, MD, is Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University and Director of the Johns Hopkins Center for TB Research and the Center for AIDS Research. Conflict of Interest: Receives consulting fees from Johnson & Johnson. Spouse has ownership interest in Merck. |
Arnab is a founding PI at Calibr at Scripps Research and currently leads the chemistry group serving as Vice President of Medicinal Chemistry. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Polly Clayden has been working as an advocate and activist for over 12 years and co-founded i-Base in April 2000 Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Dr. Cohen is President of the Hepatitis B Foundation, leading national and international efforts to eliminate hepatitis B through developing partnerships, capacity and strategies to improve hepatitis B and D screening, vaccination, and linkage to care. Conflict of Interest: Receives consulting fees (all paid directly to the Hepatitis B Foundation. She represents the Hepatitis B Foundation on community advisory boards for Gilead Sciences, Roche, Arbutus, and GSK. Also, Hepatitis B Foundation receives research and program grants from Gilead Sciences, Genentech, GSK, VBI Vaccines, and Dynavax Technologies. |
Dr. Paul L. Domanico holds a PhD in Chemistry and a Bachelor of Science degree in Pre-Medicine from Penn State University. He received his post-doctoral training in Molecular Biophysics at E.I. du Pont de Nemours and Co. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Conflicts of Interest: Dr. Jordan Feld received Personal fees for scientific consulting from: Abbott, Abbvie, Gilead, Enanta, Roche. Dr. Feld reports receiving grants for research from Abbvie, Gilead, Janssen, Wako/Fujifilm |
Simon Fletcher is a Vice President at Gilead Sciences, where he leads a group focused on developing novel therapies for acute and chronic viral infections. Conflict of interest: Dr Fletcher receives a salary from Gilead Sciences, and also holds intellectual property rights/patent, and has an ownership interest with them. |
Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Dr. Flexner reports receiving consulting income from Gilead Sciences, Merck, ViiV Healthcare, Janssen, and Theratechnologies. He also serves on a scientific advisory board for Navigen Corporation, and serves on a data safety and monitoring board for Advarra. He is a co-inventor on six issued patents related to long-acting drug delivery technology for HIV treatment and prevention. |
Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. Conflict of Interest: No disclosures. |
Elisa H. Ignatius, MD, MSc is an Assistant Professor of Medicine in the Divisions of Infectious Diseases and Clinical Pharmacology at the Johns Hopkins University School of Medicine and Program Director for the Johns Hopkins Center for Nontuberculous Mycobacteria and Bronchiectasis. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International. Conflict of Interest: No real or apparent conflicts of interest to report. |
Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. Conflict of Interest: Receives consulting fees from AbbVie, Atea, Decoy, Gilead, GlaxoSmithKline, Jannsen, Merck, Moderna, Roche, Shionogi, ViiV. Receives consulting fees for non CME/CE service from Gilead, and research funding from, Merck, and ViiV. Has an ownership interest in Decoy.. |
Imelda Mahaka is the Executive Director for Pangaea Zimbabwe AIDS Trust (PZAT). She provides strategic direction, overall oversight, coordination, and support for the implementation of PZAT programs. Conflict of Interest: |
Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. Conflict of Interest: Dr. Mirochnick has salary support through his institution for research activities from Merck, ViiV and Gilead. His wife receives salary support for research activities through her institution from ViiV. He also receives consulting fees from AstraZeneca for his serving on the DSMBs for 2 of their protocols. |
Dr. Nuermberger is an Associate Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. Conflict of Interest: Receives consulting fees from Janssen, Genentech and research funding from Janssen, TB Alliance. |
Dr Adeniyi Olagunju is a Senior Lecturer in the Department of Pharmacology and Therapeutics and a member of the Centre of Excellence for Long-acting Therapeutics (CELT), University of Liverpool, UK. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT; www.liverpool.ac.uk/CELT) at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Tandem Nano Ltd., Gilead, Assembly Biosciences. |
After his medicinal chemistry PhD and a Marie Curie Fellowship at Utrecht University, Lluis Ballell Pagès joined GlaxoSmithKline in 2005 to lead different preclinical infectious diseases projects and setup the Open Lab.. Conflict of Interest: Receives salary from, and has an ownership interest in, Johnson & Johnson. |
Dr. Chuck Peloquin received his BS in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Pharmaceutical Advocate to Médecins Sans Frontières on specific dossiers, such as access to Tuberculosis medicines. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Manuele Piccolis holds a PhD in Life Sciences from the University of Geneva and he has an extensive experience in metabolism. Conflict of Interest: Spouse receives salary support from Lunaphore Tech. |
Dr. Podany is currently an Associate Professor in the department of pharmacy practice at the University of Nebraska Medical Center. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Dr. Rangaka is an Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Bart Remmerie, Chem. Eng., graduated as a bio-engineer and as environmental engineer at Ghent University, Belgium. He started at Janssen (Bioanalysis) in 1994. Conflict of Interest: As a Janssen employee I have a wage and shares from/in the company. |
Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs. Conflict of Interest: None disclosed. |
Dr. Kimberly Scarsi is a Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy. Conflict of Interest:Receives grant funding from Viiv Healthcare Organon, LLC. |
Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina. Conflict of Interest: None disclosed. |
Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. Conflict of Interest: None disclosed. |
Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA. Conflict of Interest: Receives research grants to her institution from ViiV Healthcare. |
Dr. Norah Terrault is a transplant hepatologist, the Neil Kaplowitz Professor of Medicine and Chief of Gastrointestinal and Liver Diseases Division at the Keck School of Medicine of University of Southern California in Los Angeles, California. Conflict of Interest: Dr. Terrault receives a salary from AASLD, royalties from Elsevier, and institutional grant support from NIH; GSK; Genentech-Roche; Helio Health; Durect Corp; Eiger Pharmaceuticals, and ImmunoCore. |
David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Kati Vandermeulen, M.SC., is a Senior Director, Compound Development Team Leader at Janssen Infectious Diseases Research and Development in Beerse Belgium. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
Y. Grace Wang, MD is the VP of Clinical Development at Assembly Bioscience. Conflict of Interest: Has an ownership interest in Assembly Biosciences. |